These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37602356)

  • 1. META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports.
    Murray MM; Fakhouri L; Harpe SE
    Drugs Context; 2023; 12():. PubMed ID: 37602356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.
    Zhao AV; Crutchley RD; Guduru RC; Ton K; Lam T; Min AC
    Retrovirology; 2022 Oct; 19(1):22. PubMed ID: 36273165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Adverse Effects of HIV Integrase Inhibitors.
    Kolakowska A; Maresca AF; Collins IJ; Cailhol J
    Curr Treat Options Infect Dis; 2019; 11(4):372-387. PubMed ID: 33380904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
    Rolle CP; Castano J; Nguyen V; Patel K; Hinestrosa F; DeJesus E
    Antivir Ther; 2023 Feb; 28(2):13596535231163703. PubMed ID: 36896821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reactions to integrase strand transfer inhibitors.
    Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of different integrase strand transfer inhibitors on body weight in patients with HIV/AIDS: a network meta-analysis.
    Bai R; Lv S; Wu H; Dai L
    BMC Infect Dis; 2022 Feb; 22(1):118. PubMed ID: 35114968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
    Le Hingrat Q; Collin G; Lê M; Peytavin G; Visseaux B; Bertine M; Tubiana R; Karmochkine M; Valin N; Collin F; Lemaignen A; Bernard L; Damond F; Matheron S; Descamps D; Charpentier C;
    Clin Infect Dis; 2019 Aug; 69(4):657-667. PubMed ID: 30383215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
    Sax PE; DeJesus E; Crofoot G; Ward D; Benson P; Dretler R; Mills A; Brinson C; Peloquin J; Wei X; White K; Cheng A; Martin H; Quirk E
    Lancet HIV; 2017 Apr; 4(4):e154-e160. PubMed ID: 28219610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight Changes With Integrase Strand Transfer Inhibitor Therapy in the Management of HIV Infection: A Systematic Review.
    Hester EK; Greenlee S; Durham SH
    Ann Pharmacother; 2022 Feb; ():10600280211073321. PubMed ID: 35130714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Human Immunodeficiency Virus-1 Integrase Strand Transfer Inhibitor Resistance in British Columbia, Canada Between 2009 and 2016: A Longitudinal Analysis.
    Kamelian K; Lepik KJ; Chau W; Yip B; Zhang WW; Lima VD; Robbins MA; Woods C; Olmstead A; Joy JB; Barrios R; Harrigan PR
    Open Forum Infect Dis; 2019 Mar; 6(3):ofz060. PubMed ID: 30895202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
    Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
    Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable
    Saladini F; Giannini A; Boccuto A; Dragoni F; Appendino A; Albanesi E; Vicenti I; Zazzi M
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors.
    Hoffmann C; Llibre JM
    AIDS Rev; 2019; 21(1):4-10. PubMed ID: 30899113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.
    Dow DE; Bartlett JA
    Infect Dis Ther; 2014 Dec; 3(2):83-102. PubMed ID: 25134686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
    Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
    J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.